Our results thus allow for an unexpected alternative hypothesis for acquisition of drug resistance in breast cancer cells due to p53 loss: mutant p53 boosts mutagenic RAD52/POLθ pathways, which increase deletion and point mutations that can lead to secondary resistance mutations. This evidence concerns the gene TP53 and breast carcinoma.